Rockefeller Capital Management
BCAX

Rockefeller Capital Management’s Bicara Therapeutics BCAX Stock Holding History

Rockefeller Capital Management’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.46K Sell
285
-316
-53% -$7.05K ﹤0.01% 4080
2026
Q1 		$12K Buy
601
+480
+397% +$8.26K ﹤0.01% 3919
2025
Q4 		$2.04K Buy
+121
New +$2.07K ﹤0.01% 4311

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Rockefeller Capital Management's BCAX Position: Q2 2026 in Review

Rockefeller Capital Management reduced its Bicara Therapeutics (BCAX) stake by 53% in Q2 2026, selling an estimated $7.05K and leaving 285 shares worth $8.46K. The position accounts for ﹤0.01% of the portfolio, ranked #4080.

Rockefeller Capital Management first reported a position in BCAX in Q4 2025 and has held it in 3 quarters since. The position peaked at $12K in Q1 2026. 172 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • Rockefeller Capital Management held 285 shares of Bicara Therapeutics worth $8.46K as of Q2 2026.
  • Rockefeller Capital Management sold 316 Bicara Therapeutics shares in Q2 2026, an estimated $7.05K.
  • Bicara Therapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #4080 holding.
  • Rockefeller Capital Management first reported a position in Bicara Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Rockefeller Capital Management's Bicara Therapeutics position peaked at $12K in Q1 2026.
  • 172 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.